The Shotlee Journal
Browse Shotlee articles about Weight Management.
Showing 9 / 872 Weight Management articles
Single mum Rebecca Tidy transformed her life by losing six stone on Mounjaro, but the real game-changer was the confidence boost that doubled her income. After ditching Saxenda due to side effects, Mounjaro helped her reclaim control. Here's her inspiring journey from exhaustion to empowerment.
The latest Morning Squawk highlights the Dow's ongoing losing streak, climbing fertilizer prices, and Novo Nordisk's new Wegovy shot amid market volatility. President Trump ramps up criticism of Fed Chair Jerome Powell, urging continued investigation into the 'incompetent' leader. A judge's subpoena block adds tension to Trump's Fed nominee confirmation.
Jefferies has reiterated its Buy rating on Eli Lilly stock with a $1,300 price target, citing encouraging GLP-1 prescription data for the week ending March 13. Oral Wegovy showed strong performance in its 10th launch week, outpacing comparable injectables like Zepbound and Wegovy. Meanwhile, other GLP-1s saw slight declines amid Lilly's promising pipeline.
More than 10% of U.S. adults use GLP-1 drugs like Ozempic and Wegovy, but one in seven microdose for longevity without major weight loss or side effects, per Evidation survey. Biohackers and clinics like AgelessRx promote it for reducing inflammation and chronic disease risks. Yet experts caution on unproven claims and sourcing risks.
As GLP-1 medication use surges, a Weight Watchers report reveals medication alone isn't enough for lasting weight loss. Weight Loss Buddy emerges as a vital tool, combining AI-driven guidance and peer accountability to boost adherence and outcomes. This shift highlights the need for behavioral infrastructure in obesity treatment.
Charles Barkley's noticeably slimmer figure courtside during March Madness 2026 has sparked widespread speculation: Is Ozempic behind his weight loss? The NBA legend dropped nearly 90 pounds using GLP-1 drugs like Mounjaro and Zepbound, combined with diet and exercise. Fans are stunned, but Barkley credits hard work over hype.
Natco Pharma is shaking up India's weight-loss drug market with its generic semaglutide priced at just ₹1,290 per month—90% cheaper than Novo Nordisk's Ozempic. Launching Saturday after patent expiry, this move invites competition from Sun Pharma, Dr Reddy's, and others. Patients gain affordable access to this GLP-1 powerhouse for weight management and diabetes.
Eli Lilly announced that its next-generation obesity drug retatrutide met both primary and secondary goals in its first late-stage trial for type 2 diabetes patients. The drug achieved significant A1c reductions of 1.7% to 2% and impressive weight loss of up to 16.8% at 40 weeks. This marks a promising advancement for patients struggling with both blood sugar control and weight management.
GLP-1 drugs like Ozempic and Wegovy are reshaping eating habits, slashing demand for pastries while surging sales of protein-rich yogurt and cottage cheese. Studies show users cut grocery spending by 6-9%, favoring nutrient-dense dairy. Dairy giants like Arla and Ehrmann are capitalizing with GLP-1-friendly products.
